Biocon Biologics set to reap Biosimilar Insulin Glargine Opportunity in US
Summary : Drugmaker is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and profit…
Summary : Drugmaker is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and profit…
KEY POINTS: The U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental New Drug Application (sNDA) for Purified Cortrophin™ Gel…